776 related articles for article (PubMed ID: 22212151)
1. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
3. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
Wolf-Schnurrbusch UE; Ghanem R; Rothenbuehler SP; Enzmann V; Framme C; Wolf S
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3334-7. PubMed ID: 21087958
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
8. Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion.
Shin HJ; Chung H; Kim HC
Acta Ophthalmol; 2011 Feb; 89(1):e35-40. PubMed ID: 21155986
[TBL] [Abstract][Full Text] [Related]
9. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
Ehlers JP; Decroos FC; Fekrat S
Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
Fan C; Wang Y; Ji Q; Zhao B; Xie J
Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
[TBL] [Abstract][Full Text] [Related]
14. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
Bhisitkul RB; Campochiaro PA; Shapiro H; Rubio RG
Ophthalmology; 2013 May; 120(5):1057-63. PubMed ID: 23415775
[TBL] [Abstract][Full Text] [Related]
15. Results of bevacizumab as the primary treatment for retinal vein occlusions.
Figueroa MS; Contreras I; Noval S; Arruabarrena C
Br J Ophthalmol; 2010 Aug; 94(8):1052-6. PubMed ID: 20679089
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
17. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
[TBL] [Abstract][Full Text] [Related]
18. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
[TBL] [Abstract][Full Text] [Related]
19. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.
Kang HM; Chung EJ; Kim YM; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):501-8. PubMed ID: 22653439
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
